Abstract 67P
Background
BP02 is a trastuzumab biosimilar in development. This study evaluated equivalence of BP02 to reference trastuzumab (RT: Herceptin-EU) in HER2+ve metastatic breast cancer (MBC).
Methods
In this randomized, double-blind, parallel-group, active-controlled, multicentric, phase 3 equivalence trial, we recruited women aged 18-75 yrs with histologically/ cytologically confirmed HER2+ve, locally recurrent or MBC with systemic metastasis, from 59 sites in India. Inclusion criteria were at least one measurable lesion (RECIST 1.1), ECOG performance status of ≤2, probable life expectancy of ≥18 mths, LVEF ≥55%, adequate renal, hepatic, and hematological functions. Exclusion criteria included contralateral breast cancer, cancer of any other site, metastases to brain and spinal cord; previous exposure to any prior therapy to metastatic disease; serious cardiac illness and known hypersensitivity to trastuzumab. We randomly allocated patients 1:1 stratified by ER and PR status to receive BP02 or RT (8mg/kg loading dose on day 1 of cycle 1, 6mg/kg on day 1 of cycles 2-8, each cycle lasting 3 wks) combined with docetaxel (75mg/m2 on day 1 of cycles 1-8) [induction phase]. Participants with complete or partial response, or stable disease at end of induction phase continued the study drug until disease progression or treatment discontinuation [maintenance phase]. Participants and investigators were masked to treatment until study completion. The primary efficacy endpoint was objective response rate (ORR) as per RECIST 1.1. Results of induction phase are presented.
Results
Between 23-Sep-2020 and 16-Sep-2022, we randomly allocated 690 patients (n=345 each to BP02 and RT). In the ITT population, similar proportion of patients achieved ORR with BP02 (n=231, 67.0%, 95% CI 62.0, 71.9) and RT (n=238, 69.0%, 95% CI 64.1, 73.9). 95% CI of risk difference (-2.03, 95% CI -9.15, 5.09) was within the equivalence margins of ±13%. 90% CI of risk ratio (0.97, 90% CI 0.89, 1.06) was within the equivalence margins of (0.80, 1.25). TEAEs were seen in 58% and 60.3% patients; TEAEs leading to treatment withdrawal were reported in 2.9% and 3.2% patients, with BP02 and RT respectively.
Conclusions
BP02 showed equivalent efficacy and similar safety profile to RT.
Clinical trial identification
CTRI/2020/04/024456.
Editorial acknowledgement
Dr Vallish BN from MarksMan Healthcare Communications, India provided editorial assistance in writing of the abstract.
Legal entity responsible for the study
Curateq Biologics Private Limited, Hyderabad, India.
Funding
Curateq Biologics Private Limited, Hyderabad, India.
Disclosure
A. Prajapati, D. Dadke: Financial Interests, Personal, Full or part-time Employment: Curateq biologics. R.K. Kothari: Financial Interests, Personal, Financially compensated role: Zydus Pharmaceuticals, AstraZeneca, Glenmark, Novartis, Emcure, Fresenius Kabi, Bard Peripheral Vascular, Pfizer, Alkem Laboratories, Roche; Financial Interests, Institutional, Financially compensated role: Cipla, Merck, Celon Pharma, Bristol Myers Squibb Foundation; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Institutional, Research Funding: Zydus Pharmaceuticals, Lambda Therapeutic Research, Axis Clinicals, Reliance Life Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract